We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAthersys, Inc.

Athersys, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
16426
Market Cap
0.01M

Momentum Score

…

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
-
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Athersys, Inc. is a clinical-stage biotechnology company developing regenerative cell therapies based on its MultiStem platform for inflammatory, ischemic and immune-mediated conditions. Long-term growth may be driven by successful trials, regulatory approvals and licensing or commercialization deals that could support wider adoption of its allogeneic MultiStem platform, which may appeal to investors seeking exposure to regenerative medicine.
Key investment risks include failure in clinical development or regulatory review, limited or no commercial revenue, ongoing financing needs and low liquidity associated with its OTC/PINK listing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.08M
Revenue Per Share
0.00
Gross Profit TTM
-18.70M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
718.84%
Diluted EPS TTM
-16.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -72.53M -86.95M -78.77M -44.58M
Net income -72.53M -86.95M -78.77M -44.58M
Selling general administrative 15.88M 20.07M 15.89M 11.38M
Reconciled depreciation 1.42M 1.43M 0.89M 0.70M
Operating income -77.01M -87.06M -78.33M -45.49M
Total revenue 5.33M 5.51M 1.43M 5.52M
Total operating expenses 82.33M 92.57M 79.76M 51.01M
Total other income expense net 4.47M 0.10M -0.43M 0.91M
Net income from continuing ops -72.53M -86.95M -78.77M -44.58M
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 27.73M 60.18M 59.71M 41.67M
Other current assets 1.03M 1.34M 2.93M 1.19M
Total liab 51.58M 43.81M 28.35M 18.39M
Total stockholder equity -23.85M 16.37M 31.36M 23.27M
Other current liab 0.53M - - -
Capital stock 0.02M 0.01M 0.20M 0.16M
Retained earnings -655.88M -583.34M -496.39M -417.62M
Cash 9.04M 37.41M 51.55M 35.04M
Total current liabilities 38.44M 29.86M 22.95M 12.84M
Total current assets 13.54M 46.03M 54.56M 37.17M
Net receivables 0.72M 1.41M 0.09M 0.94M
Accounts payable 27.77M 16.90M 13.04M 10.12M
Non currrent assets other 2.14M 1.50M 1.35M 1.61M
Non current assets total 14.20M 14.16M 5.15M 4.50M
Capital lease obligations 8.69M 9.77M 0.68M -
Breakdown 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly
Date 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -0.26M -1.36M -1.16M -0.58M
Total cash from financing activities 30.84M 63.41M 79.48M 19.89M
Net income -72.53M -86.95M -78.77M -44.58M
Change in cash -28.37M -14.14M 16.50M -16.02M
Begin period cash flow 37.41M 51.55M 35.04M 51.06M
End period cash flow 9.04M 37.41M 51.55M 35.04M
Total cash from operating activities -58.95M -76.19M -61.81M -35.33M
Issuance of capital stock 31.02M 64.26M 72.78M 20.31M
Depreciation 1.42M 1.43M 0.89M 0.70M
Change to account receivables 3.70M -4.33M 0.86M 3.78M
Capital expenditures 0.40M 1.36M 1.16M 0.58M
Change in working capital 2.95M 0.55M 8.69M 3.71M
Stock based compensation 6.20M 8.56M 7.38M 4.85M
Other non cash items - 0.23M - -
Free cash flow -59.35M -77.55M -62.97M -35.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Athersys, Inc.

Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.

3201 Carnegie Avenue, Cleveland, OH, United States, 44115-2634

216 431 9900

https://www.athersys.com

24

Name Title Year Born
Ms. Z. Kasey Rosado Interim CFO & Director 1974
Senthil Ranganathan Ph.D. Vice President of Technical Operations NA
Mr. David Russ M.B.A. Vice President of Supply Chain, Finance & Administration NA
Dr. Manal Morsy M.B.A., M.D., PH.D. Executive VP & Head of Global Regulatory Affairs NA
Dr. Robert Mays Ph.D. Executive VP, Head of Regenerative Medicine & Neuroscience Programs NA
Mr. Rakesh Ramachandran MS Head of Information Technology & Communications and VP NA
Dr. Sarah Busch Ph.D. VP of Regenerative Medicine & Head of Business Development NA
Ms. Ellen Gurley Manager of Corporate Communications and Investor Relations NA
Dr. Senthil Ranganathan Ph.D. Vice President of Technical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…